4D Molecular Therapeutics
FDMT | NASDAQ
$11.29
-$0.94 (-7.69%)
At close: Nov 16, 2026, 4:00 PM ET
$11.29
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
4D Molecular Therapeutics Company Profile
Company profile explainedCompany Profile
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Key Executives
| Name | Position |
|---|---|
| David H. Kirn | Co-Founder, President, CEO & Director |
| Scott Bizily | Chief Legal Officer & Corporate Secretary |
| An Song | Chief Translational Medicine Advisor |
| Fariborz Kamal | Chief Technical Advisor |
| John F. Milligan | Executive Chairman |
| Julian Pei | Head of Investor Relations & Corporate Finance |
| Katy Barglow | Chief Technical Officer |
| Kristian Humer | CFO and Principal Financial & Accounting Officer |
| Noriyuki Kasahara | Chief Scientific Advisor |
| Theresa Janke | Co-Founder & Chief of Staff |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 20, 2026 | 4 | Filing |
| Oct 07, 2026 | 4 | Filing |
| Sep 28, 2026 | 8-K | Current Report |
| Sep 22, 2026 | 4 | Filing |
| Sep 16, 2026 | 4 | Filing |
| Sep 03, 2026 | 4 | Filing |
| Aug 21, 2026 | 4 | Filing |
| Aug 17, 2026 | 4 | Filing |
| Aug 13, 2026 | 10-Q | Quarterly Report |
| Aug 13, 2026 | 8-K | Current Report |
4D Molecular Therapeutics
| Country | United States |
| IPO Date | Dec 11, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 196 |
| CEO | David H. Kirn |
Contact Details
5858 Horton Street EmeryVille,
California 94608 United States
Stock Details
| Ticker Symbol | FDMT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001650648 |
| CUSIP Number | 35104E100 |
| ISIN Number | US35104E1001 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove FDMT